‘Syria Tomorrow’ opposition leader counts on Russia’s role in settling crisisWorld June 22, 14:26
Rosneft plans to increase oil refining in 2017Business & Economy June 22, 13:54
Putin lays wreath at Tomb of Unknown Soldier in MoscowSociety & Culture June 22, 13:49
Diplomat castigates US remarks against Russian-Serbian center as ‘absurd’Russian Politics & Diplomacy June 22, 13:48
Terror attack in southern Afghanistan kills 29World June 22, 13:26
Press review: Trump not giving Kiev 'money for nothing' and UN picks counterterror chiefPress Review June 22, 13:00
Russia awaits West’s reaction to ‘unidentified aircraft’ supporting IS in AfghanistanRussian Politics & Diplomacy June 22, 12:56
Iskander missile system drills held in eastern RussiaMilitary & Defense June 22, 12:56
Gazprom, Asian banks discuss Nord Stream-2 financingBusiness & Economy June 22, 12:22
GENEVA, June 14. /TASS/. The Court of Arbitration for Sport announced on Tuesday that it would announce its decision regarding an appeal from Russian tennis player Maria Sharapova before July 18.
According to various media reports earlier in the day, tennis star Sharapova has filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed last week by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
"In her appeal to the CAS, Ms Sharapova seeks the annulment of the Tribunal’s decision to sanction her with a two-year period of ineligibility further to an anti-doping rule violation," the CAS said in its statement. "Ms Sharapova submits that the period of ineligibility should be eliminated, or in the alternative, reduced."
"The parties have agreed to an expedited procedure which will allow the CAS to render a decision, at the latest, on 18 July 2016," the statement added.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.